MIR29B1

Summary

MIR29B1 (microRNA 29b-1, HGNC:31619) is a microRNA gene on chromosome 7q32.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407024 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31619
Approved symbol	MIR29B1
Name	microRNA 29b-1
Location	7q32.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-29b-1
Ensembl gene	ENSG00000283797
Ensembl biotype	miRNA
OMIM	610783
Entrez	407024
RNAcentral	URS0000150A7D — miRNA, 81 nt, 32 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385015

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385015 — 1 exons

Exon	Start	End
ENSE00001500022	130877459	130877539

Expression profiles

Bgee: expression breadth tissue_specific, 5 present calls, max score 94.38.

Top tissues by expression

5 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	94.38	gold quality
subcutaneous adipose tissue	UBERON:0002190	60.28	gold quality
skin of leg	UBERON:0001511	58.68	gold quality
omental fat pad	UBERON:0010414	52.56	gold quality
blood	UBERON:0000178	46.53	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1

Literature-anchored findings (GeneRIF, showing 40)

• miR-29b predominantly localized to the nucleus; the hexanucleotide terminal motif of miR-29b acts as a transferable nuclear localization element that directs nuclear enrichment of miRNAs or small interfering RNAs to which it is attached (PMID:17204650)
• Loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic Alzheimer’s disease. (PMID:18434550)
• Down-regulation of DNMT3A & DNMT3B results from direct interaction of miR-29b with the 3’ untranslated regions of these genes. miR-29b down-regulates DNMT1 indirectly by targeting Sp1. (PMID:19211935)
• MiR-29b negatively regulates the expression of multiple genes involved in the synthesis and deposition of extracellular matrix in trabecular meshwork (TM) cells. (PMID:19956414)
• The ability of LMP1 to negatively regulate TCL1 through miR-29b might underlie its B-cell lymphoma growth antagonistic property. (PMID:19966860)
• These findings identify miR-29b as a novel posttranscriptional regulator of PGRN expression, raising the possibility that miR-29b or other miRNAs might be targeted therapeutically to increase hPGRN levels in some frontotemporal dementia patients. (PMID:20479936)
• Results indicate that in addition to c-Myc, mir-29b-1/mir-29a expression can be suppressed by hedgehog signaling and inflammatory pathways, both commonly activated in the genesis of malignancies. (PMID:20564213)
• Data showed that miR-29b expression was increased 4-fold in indolent CLL and 3.5-fold in aggressive CLL. (PMID:20566844)
• CEBPA selectively regulates miR-29b expression on its miR-29a/b1 locus on chromosome 7q32.3. (PMID:20628397)
• Aberrant expression of miR-29b, which modulates PTEN expression, can contribute to migration, invasion, and anti-apoptosis (PMID:21359530)
• MIR-29b deregulation contributes to angiogenesis, invasion, and metastasis of hepatocellular carcinoma. (PMID:21793034)
• MicroRNA-29b was profoundly increased in biopsies of human thoracic aneurysms. (PMID:21903938)
• These findings suggest that miRNA-29b may play an important role in MM as a tumor suppressor. (PMID:21951844)
• Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. (PMID:22096249)
• microRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells. (PMID:22716646)
• MiR-29 expression is suppressed by progestins in breast cancer cells. (PMID:22751119)
• Results suggest that miR-29b negatively regulates DNA methyltransferase 1 (DNMT1) expression by targeting sp1 in T cells. Overexpression of miR-29b contributes to reduction of DNMT1 levels and DNA hypomethylation in systemic lupus erythematosus. (PMID:23142053)
• Sp1 is a negative regulator of miR-29b expression in multiple myeloma cells. (PMID:23190608)
• enforced expression of miR-29b impairs osteoclast (OCL) differentiation and overcomes OCL activation triggered by multiple myeloma cells (PMID:23254643)
• miR-26a/b and miR-29b are upregulated during osteogenic differentiation of unrestricted somatic stem cells and share target genes inhibiting osteogenesis (PMID:23418963)
• miR-29b may function as a tumor suppressor by targeting ABL1 and BCR/ABL1. (PMID:23428668)
• MiR29b expression was also reduced in the atria of chronic atrial fibrillation patients (by 54% versus sinus rhythm; p<0.05). (PMID:23459615)
• Data show that TLR3 activation by poly I-C induces up-regulation of microRNA-29b, -29c, -148b, and -152 targeting DNA methyltransferases, leading to demethylation and reexpression of the oncosuppressor retinoic acid receptor beta (RARbeta). (PMID:23716670)
• miR-29s suppresses the Wnt signaling pathway through demethylation of WIF-1 in non-small-cell lung cancer. (PMID:23939044)
• The miR-29s acted as tumour suppressors and directly targeted laminin-integrin signalling in head and neck squamous cell carcinoma. (PMID:24091622)
• miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. (PMID:24147037)
• tissue inhibitor of metalloproteinase (TIMP)-1 ratio were detected when the scaffolds were functionalized with miR-29B (PMID:24402185)
• miR-29b downregulation is essential for pathogenesis of uterine leiomyoma (PMID:24424054)
• serum levels of miR-29 were lower in patients with stricturing disease compared with those without. These findings implicate the miR-29 family in the pathogenesis of intestinal fibrosis in Crohn’s disease. (PMID:24641356)
• miR-29b down-regulates HSP47 and LOX expression. (PMID:24650661)
• Id-1, a protein repressed by miR-29b, facilitates TGFbeta1-induced EMT in human ovarian cancer cells and represents a promising therapeutic target for treating ovarian cancer. (PMID:24662327)
• miR-29b mRNA, MAPK10 protein expression, and ATG9A protein expression are closely related to chemosensitivity of ovarian carcinoma. (PMID:24767251)
• miR-29b show lower expression levels during osteoblast differentiation of bone marrow stromal cells from Osteogenesis Imperfecta patients (PMID:24767406)
• Study revealed that tumor-suppressive miR-29s regulated cancer pathways. (PMID:24820027)
• the decrease in the expression of miR-29b by c-Myc may be responsible for FHIT loss-mediated tumor aggressiveness and for poor outcome in non-small cell lung cancer. (PMID:24909176)
• Results show that miR- 29b negatively regulates Wnt signaling in human colorectal cancer cells and targets BCL9L, TCF7L2, and SNAI1. (PMID:24913975)
• Serum levels of miR-29a and miR-29b were both independent prognostic factors for overall survival and disease-free survival of osteosarcoma patients. (PMID:25015394)
• MiR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression. (PMID:25032858)
• Levels of hsa-miR-29b-3p, hsa-miR-33a-5p and hsa-miR-146a-5p are higher in plasma from elite controllers than chronic infected HIV patients. (PMID:25081906)
• Results show that aberrant miR-29 expression may account for reduced NMI expression in breast tumors and mesenchymal phenotype of cancer cells that promotes invasive growth. (PMID:25174825)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir29b-1	ENSMUSG00000065604

Paralogs (3): MIR29A (ENSG00000284032), MIR29B2 (ENSG00000284203), MIR29C (ENSG00000284214)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.